



Media Release

4 October 2018

PHARMAXIS NON EXECUTIVE DIRECTOR DR SIMON BUCKINGHAM TO RETIRE AT 2018 ANNUAL GENERAL MEETING

Pharmaceutical research company Pharmaxis (ASX: PXS) today announced that its non-executive director Dr Simon Buckingham will retire at the conclusion of his current term at the 2018 annual general meeting, to be held on 22 November 2018.

Dr Buckingham joined the Pharmaxis Board in July 2012 and has served as a non-executive director for two terms of three years each, a critical time which has seen the Company repositioned as a drug developer focussed on inflammatory and fibrotic diseases.

Pharmaxis Chairman Malcolm McComas said, "Simon's significant career experience in drug development, commercialisation and partnering with large pharma companies has been immensely valuable to Pharmaxis as we reorganized the business and then negotiated important partnerships with Chiesi and Boehringer Ingelheim. We recognise his considerable contribution as a director over a sustained period and wish him well as he moves into other areas."

Dr Buckingham intends to direct his time towards early stage private companies, not-for-profit foundations and advisory opportunities. He has agreed to consult to Pharmaxis to provide assistance with current partnering discussions including the Company's LOXL2 program.

#ends#

SOURCE: Pharmaxis Ltd, Sydney, Australia

CONTACT: Felicity Moffatt, phone +61 418 677 701 or email felicity.moffatt@pharmaxis.com.au

About Pharmaxis

Pharmaxis (ACN 082 811 630) is an Australian pharmaceutical research company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval. Its product Bronchitol® for cystic fibrosis is marketed in Europe, Russia and Australia. Its product Aridol® for the assessment of asthma is sold in Europe, Australia and Asia. The company's development pipeline is centred on its expertise in amine oxidase chemistry and includes a series of Lysyl Oxidase Inhibitors under clinical development targeting fibrotic diseases of the heart, kidney, liver and lung. In May 2015, Boehringer Ingelheim acquired the Pharmaxis investigational drug PXS-4728A, a potent inhibitor of Semicarbazide-Sensitive Amine Oxidase (SSAO), to develop it for the treatment of the liver-related condition Non-alcoholic Steatohepatitis (NASH) and other inflammatory diseases. Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company's head office, manufacturing and research facilities are located in Sydney, Australia. For more information about Pharmaxis, please see www.pharmaxis.com.au

Forward-Looking Statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.